Sign In
Buy OGEN
$0.610
+0 (+0%)
At Close: Jun 03, 2026
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
01:30pm, Monday, 02'nd Dec 2019
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced the completion of en
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publicatio
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces the company’s Senior Vi
Oragenics, Inc. to Present at the BIO Investor Forum
12:00pm, Tuesday, 22'nd Oct 2019
Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will be presenting
OGEN: Phase 2 Trial of AG013 More Than 2/3rd Enrolled…
12:15pm, Wednesday, 02'nd Oct 2019
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Poster on Phase 2 Trial of AG013 Presented at ESMO 2019 On September 30, 2019, Oragenics, Inc. (NYSE:OGEN) announced th
Oragenics Presents Interim Data on The AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
12:00pm, Monday, 30'th Sep 2019
Oragenics, Inc. (NYSE American:OGEN) (“Oragenics”), a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, today announces initia
The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear
12:00am, Sunday, 29'th Sep 2019Oragenics, Inc. Announces Phase 2 Clinical Trial of AG013 Reaches Enrollment of 158 Patients
12:00pm, Wednesday, 25'th Sep 2019
Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announces it has enrolled 158 patie
